[1] Zhou P,Yang XL,Wang XG, et al.A Pneumonia Outbreak Associated with A New Coronavirus of Probable Bat Origin[J]. Nature, 2020,579(7798):270-273. [2] Phelan AL, Katz R, Gostin LO.The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance[J]. JAMA,2020,323(8):709-710. [3] Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. Lancet, 2020,395(10223):497-506. [4] Zhu N, Zhang D, Wang W, et al.A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med. 2020,382(8):727-733. [5] 严珺,尹文,张侃.新型冠状病毒(SARS-CoV-2)对血液安全的影响[J/OL].临床输血与检验:1-7[2020-04-12].http://kns.cnki.net/kcms/detail/34.1239.R.20200312.1054.002.html. [6] 王世春,阮潜瑛,刁荣华,等.COVID-19流行期间采供血工作特点及对策[J/OL].临床输血与检验:1-5[2020-04-12].http://kns.cnki.net/kcms/detail/34.1239.r.20200320.1916.002.html. [7] 中华人民共和国国家卫生健康委员会.关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知(国卫办医函〔2020〕184号 )[EB/OL](2020-03-04).http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. [8] 张立波,戴宇东,庞蓉蓉,等.血站实验室新型冠状病毒相关检测平台的建立与安全防护[J/OL].临床输血与检验:1-6[2020-04-12].http://kns.cnki.net/kcms/detail/34.1239.r.20200309.2131.002.html. [9] Stockman LJ, Bellamy R, Garner P.SARS: Systematic review of treatment effects[J]. PLoS Med, 2006, 3(9):e343. [10] YIN S J. Chinese biology: plasma products from recovered patients were put into clinical practice, and signs and symptoms of the patients improved significantly [EB/OL](2020-02-14).http://www.xinhuanet.com//2020-02/14/c_1125573091.htm. [11] 徐万洲, 李娟, 何晓云, 等. 血清2019新型冠状病毒IgM和IgG抗体联合检测在新型冠状病毒感染中的诊断价值 [J/OL] . 中华检验医学杂志,2020,43 (2020-02-27).http://rs.yiigle.com/yufabiao/1182736.htm. DOI: 10.3760/cma.j.cn114452-20200223-00109. [12] Wagner SJ.Virus inactivation in blood components by photoactive phenothiazinedyes[J].Transfus Med Rev, 2002 ,16(1):61-66. [13] 马平,周锡鹏,张艳宇,等.亚甲蓝/光化学灭活病毒法对血浆中抗体活性的影响[J].军事医学科学院刊,2004,28(6):544-564. |